{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-001434","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2023-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.619940+00:00","generated_at":"2026-06-19T23:17:44.100112+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tenax Therapeutics raises ~$15.6M in public offering of common stock and warrants","bullets":["Priced 8,666,666 shares (or pre-funded warrants) plus 17,333,332 warrants at $1.80/unit.","Gross proceeds ~$15.6M; net proceeds ~$14.1M after fees and expenses.","Warrants exercisable at $2.25/share, expire 5 years from issuance.","Proceeds to fund Phase 3 trial of imatinib for PAH and levosimendan for PH-HFpEF.","Offering closed Feb 7, 2023; post-closing shares outstanding 9,265,099."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-001434","json":"https://secwatch.observer/filing/0001654954-23-001434.json","markdown":"https://secwatch.observer/filing/0001654954-23-001434.md","text":"https://secwatch.observer/filing/0001654954-23-001434.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495423001434/0001654954-23-001434-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495423001434/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T23:17:44.100112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22369a745921433a8705e2b11377a2c524b2a96f","claim":"TENAX THERAPEUTICS, INC. entered into Securities Purchase Agreement with certain purchasers valued at Gross proceeds of approximately $15.6 million (effective 2023-02-03).","evidence_excerpt":"On February 3, 2023, Tenax Therapeutics, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of (i) an aggregate of 6,959,444 shares of its common stock, par value $0.0001 per share (“Common Stock”) and pre-funded warrants to purchase an aggregate of 1,707,222 shares of Common Stock (the “Pre-Funded Warrants”) and (ii) accompanying warrants to purchase up to an aggregate of 17,333,332 shares of its Common Stock (the “Common Warrants”) at a combined offering price of $1.80 per share of Common Stock and associated Common Warrant, or $1.799 per Pre-Funded Warrant and associated Common Warrant, resulting in gross proceeds of approximately $15.6 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000165495423001434/0001654954-23-001434-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain purchasers"},{"label":"Value","value":"Gross proceeds of approximately $15.6 million"},{"label":"Effective","value":"2023-02-03"}],"fact_type":"material_agreement"},{"claim_id":"55d24df1528a153d42a35a1248a8a7073c28e52c","claim":"TENAX THERAPEUTICS, INC. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at Cash fee of 7% of aggregate gross proceeds raised in the Public Offering (effective 2023-02-03).","evidence_excerpt":"(the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of (i) an aggregate of 6,959,444 shares of its common stock, par value $0.0001 per share (“Common Stock”) and pre-funded warrants to purchase an aggregate of 1,707,222 shares of Common Stock (the “Pre-Funded Warrants”) and (ii) accompanying warrants to purchase up to an aggregate of 17,333,332 shares of its Common Stock (the “Common Warrants”) at a combined offering price of $1.80 per share of Common Stock and associated Common Warrant, or $1.799 per Pre-Funded Warrant and associated Common Warrant, resulting in gross proceeds of approximately $15.6 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000165495423001434/0001654954-23-001434-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Roth Capital Partners, LLC"},{"label":"Value","value":"Cash fee of 7% of aggregate gross proceeds raised in the Public Offering"},{"label":"Effective","value":"2023-02-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}